Literature DB >> 22114827

Anticoagulation-associated adverse drug events.

Gregory Piazza1, Thanh Nha Nguyen, Deborah Cios, Matthew Labreche, Benjamin Hohlfelder, John Fanikos, Karen Fiumara, Samuel Z Goldhaber.   

Abstract

PURPOSE: Anticoagulant drugs are among the most common medications that cause adverse drug events (ADEs) in hospitalized patients. We performed a 5-year retrospective study at Brigham and Women's Hospital to determine clinical characteristics, types, root causes, and outcomes of anticoagulant-associated ADEs.
METHODS: We reviewed all inpatient anticoagulant-associated ADEs, including adverse drug reactions (ADRs) and medication errors, reported at Brigham and Women's Hospital through the Safety Reporting System from May 2004 to May 2009. We also collected data about the cost associated with hospitalizations in which ADRs occurred.
RESULTS: Of 463 anticoagulant-associated ADEs, 226 were medication errors (48.8%), 141 were ADRs (30.5%), and 96 (20.7%) involved both a medication error and ADR. Seventy percent of anticoagulant-associated ADEs were potentially preventable. Transcription errors (48%) were the most frequent root cause of anticoagulant-associated medication errors, while medication errors (40%) were a common root cause of anticoagulant-associated ADRs. Death within 30 days of anticoagulant-associated ADEs occurred in 11% of patients. After an anticoagulant-associated ADR, most hospitalization expenditures were attributable to nursing costs (mean $33,189 per ADR), followed by pharmacy costs (mean $7451 per ADR).
CONCLUSION: Most anticoagulant-associated ADEs among inpatients result from medication errors and are, therefore, potentially preventable. We observed an elevated 30-day mortality rate among patients who suffered an anticoagulant-associated ADE and high hospitalization costs following ADRs. Further quality improvement efforts to reduce anticoagulant-associated medication errors are warranted to improve patient safety and decrease health care expenditures.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22114827      PMCID: PMC3224344          DOI: 10.1016/j.amjmed.2011.06.009

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  23 in total

1.  Are data from clinical registries of any value?

Authors:  J S Alpert
Journal:  Eur Heart J       Date:  2000-09       Impact factor: 29.983

2.  Multifaceted approach to reducing preventable adverse drug events.

Authors:  Jon B Silverman; Carl D Stapinski; William W Churchill; Camilla Neppl; David W Bates; Tejal K Gandhi
Journal:  Am J Health Syst Pharm       Date:  2003-03-15       Impact factor: 2.637

3.  Medication errors associated with anticoagulant therapy in the hospital.

Authors:  John Fanikos; Carl Stapinski; Sophia Koo; Nils Kucher; Kanella Tsilimingras; Samuel Z Goldhaber
Journal:  Am J Cardiol       Date:  2004-08-15       Impact factor: 2.778

Review 4.  Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues.

Authors:  M H Eckman; H J Levine; S G Pauker
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

5.  Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group.

Authors:  D W Bates; D J Cullen; N Laird; L A Petersen; S D Small; D Servi; G Laffel; B J Sweitzer; B F Shea; R Hallisey
Journal:  JAMA       Date:  1995-07-05       Impact factor: 56.272

6.  The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.

Authors:  D W Bates; N Spell; D J Cullen; E Burdick; N Laird; L A Petersen; S D Small; B J Sweitzer; L L Leape
Journal:  JAMA       Date:  1997 Jan 22-29       Impact factor: 56.272

7.  Adverse drug reaction risk factors in older outpatients.

Authors:  Emily R Hajjar; Joseph T Hanlon; Margaret B Artz; Catherine I Lindblad; Carl F Pieper; Richard J Sloane; Christine M Ruby; Kenneth E Schmader
Journal:  Am J Geriatr Pharmacother       Date:  2003-12

8.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-02       Impact factor: 91.245

9.  Adverse drug events in hospitalized patients treated with cardiovascular drugs and anticoagulants.

Authors:  R Zaidenstein; S Eyal; S Efrati; L Akivison; M Koren Michowitz; V Nagornov; A Golik
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002 Apr-May       Impact factor: 2.890

10.  Systems analysis of adverse drug events. ADE Prevention Study Group.

Authors:  L L Leape; D W Bates; D J Cullen; J Cooper; H J Demonaco; T Gallivan; R Hallisey; J Ives; N Laird; G Laffel
Journal:  JAMA       Date:  1995-07-05       Impact factor: 56.272

View more
  32 in total

1.  Severity and management of drug-drug interactions in acute geriatric patients.

Authors:  Marianne Lea; Stine Eidhammer Rognan; Radojka Koristovic; Torgeir Bruun Wyller; Espen Molden
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

Review 2.  Systems-based hematology: highlighting successes and next steps.

Authors:  Jori E May; Patrick C Irelan; Kailee Boedeker; Emily Cahill; Steven Fein; David A Garcia; Lisa K Hicks; Janice Lawson; Ming Y Lim; Colleen T Morton; Anita Rajasekhar; Satish Shanbhag; Marc S Zumberg; Robert M Plovnick; Nathan T Connell
Journal:  Blood Adv       Date:  2020-09-22

Review 3.  Regulatory, legislative, and policy updates with anticoagulant use.

Authors:  John Fanikos; Leo F Buckley; Ahmed Aldemerdash; Kimberly J Terry; Gregory Piazza; Jean M Connors; Samuel Z Goldhaber
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

4.  Medical Care Tasks among Spousal Dementia Caregivers: Links to Care-Related Sleep Disturbances.

Authors:  Courtney A Polenick; Amanda N Leggett; Donovan T Maust; Helen C Kales
Journal:  Am J Geriatr Psychiatry       Date:  2018-02-01       Impact factor: 4.105

5.  Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study.

Authors:  Anne-Laure Sennesael; Anne-Sophie Larock; Bérangère Devalet; Valérie Mathieux; Franck Verschuren; Xavier Muschart; Olivia Dalleur; Jean-Michel Dogné; Anne Spinewine
Journal:  Br J Clin Pharmacol       Date:  2018-04-17       Impact factor: 4.335

Review 6.  Prevention of Stroke by Antithrombotic Therapy in Patients with Atrial Fibrillation.

Authors:  Athanasios J Manolis; Leonidas E Poulimenos
Journal:  J Atr Fibrillation       Date:  2013-02-12

7.  Systematic review of interventions to improve safety and quality of anticoagulant prescribing for therapeutic indications for hospital inpatients.

Authors:  Andrew Frazer; James Rowland; Alison Mudge; Michael Barras; Jennifer Martin; Peter Donovan
Journal:  Eur J Clin Pharmacol       Date:  2019-09-11       Impact factor: 2.953

Review 8.  Impact of target-specific oral anticoagulants on transitions of care and outpatient care models.

Authors:  Ann K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 9.  Recent clinical trials in atrial fibrillation in hypertensive patients.

Authors:  Athanasios J Manolis; Manolis S Kallistratos; Leonidas E Poulimenos
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

10.  Prevalence of adverse drug reactions in the primary care setting: A systematic review and meta-analysis.

Authors:  Widya N Insani; Cate Whittlesea; Hassan Alwafi; Kenneth K C Man; Sarah Chapman; Li Wei
Journal:  PLoS One       Date:  2021-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.